Here's what the exact wording was by the company:
Post# of 72447
Posted On: 05/13/2016 1:43:42 AM
Re: Chopper101 #22423
Here's what the exact wording was by the company:
This is a small company running 4 clinical trials right now. They're referring to a meeting with the FDA to start ANOTHER NEW clinical trial. If I were running the company, I wouldn't want to try to do too many things at once. Remember that they have to do data analysis very soon, now that some of the clinical trials are reaching a point where results can be released. With so many things going on, and a limited amount of time the staff has, I think it's smart not to be trying to do too many things at once. Also, the issue of paying for yet another clinical trial is why many of us think the company did some fund raising via the Aspire financing deal.
Makes perfect sense to me that you make sure you can handle everything you've got going, before you start something else.
I see absolutely no basis in fact for inferring that "they are discontinuing Prurisol." In fact their statement that they're going to be releasing raw data a week after this phase concludes indicates to me that they are very confident in excellent results. If someone's NOT confident, they would want time to look at the data and see if there is any way to spin it as positive. If it's so good that a positive interpretation is obvious, you don't need to do that.
As far as phase 2 being sufficient for them to go to the FDA right now, some of us have speculated on that being the case. We'd all be happy to see that
Quote:
Cellceutix previously filed the request, ultimately electing to hold off on clinical studies of Brilacidin for dermatological uses until several other clinical trials sponsored by the Company were completed or neared completion.
This is a small company running 4 clinical trials right now. They're referring to a meeting with the FDA to start ANOTHER NEW clinical trial. If I were running the company, I wouldn't want to try to do too many things at once. Remember that they have to do data analysis very soon, now that some of the clinical trials are reaching a point where results can be released. With so many things going on, and a limited amount of time the staff has, I think it's smart not to be trying to do too many things at once. Also, the issue of paying for yet another clinical trial is why many of us think the company did some fund raising via the Aspire financing deal.
Makes perfect sense to me that you make sure you can handle everything you've got going, before you start something else.
I see absolutely no basis in fact for inferring that "they are discontinuing Prurisol." In fact their statement that they're going to be releasing raw data a week after this phase concludes indicates to me that they are very confident in excellent results. If someone's NOT confident, they would want time to look at the data and see if there is any way to spin it as positive. If it's so good that a positive interpretation is obvious, you don't need to do that.
As far as phase 2 being sufficient for them to go to the FDA right now, some of us have speculated on that being the case. We'd all be happy to see that
(1)
(0)